Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H9WY
|
|||
| Former ID |
DNCL002905
|
|||
| Drug Name |
PAZ-320
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
Boston Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Intestinal maltase-glucoamylase (MGAM) | Target Info | Modulator | [2] |
| KEGG Pathway | Galactose metabolism | |||
| Starch and sucrose metabolism | ||||
| Metabolic pathways | ||||
| Carbohydrate digestion and absorption | ||||
| Pathwhiz Pathway | Starch and Sucrose Metabolism | |||
| WikiPathways | Metabolism of carbohydrates | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02060916) Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes. U.S. National Institutes of Health. | |||
| REF 2 | Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.